Lead Story
WHO validates Timor-Leste as trachoma-free, clearing the disease from all of South-East Asia
The World Health Organization announced on September 3, 2026, that it has validated Timor-Leste's elimination of trachoma as a public health problem, making it the last country in the WHO South-East Asia Region with suspected endemic trachoma to reach that milestone. Trachoma is the world's leading infectious cause of blindness, and the validation followed a rigorous, multi-year process documenting health improvements across the country. Specialized services, including trichiasis surgery, remain available through the National Eye Centre at Hospital Nacional Guido Valadares in Dili, and trachoma surveillance will now be folded into Timor-Leste's routine disease-monitoring systems as the WHO region marks a key step toward its 2030 goal of eliminating trachoma worldwide.
Read more →Lead Story
WHO validates Timor-Leste as trachoma-free, clearing the disease from all of South-East Asia
The World Health Organization announced on September 3, 2026, that it has validated Timor-Leste's elimination of trachoma as a public health problem, making it the last country in the WHO South-East Asia Region with suspected endemic trachoma to reach that milestone. Trachoma is the world's leading infectious cause of blindness, and the validation followed a rigorous, multi-year process documenting health improvements across the country. Specialized services, including trichiasis surgery, remain available through the National Eye Centre at Hospital Nacional Guido Valadares in Dili, and trachoma surveillance will now be folded into Timor-Leste's routine disease-monitoring systems as the WHO region marks a key step toward its 2030 goal of eliminating trachoma worldwide.
US clean energy deployment hits a record high, now enough to power 83 million homes
The American Clean Power Association reported on September 3, 2026, that US clean energy deployment reached a record high in the first half of 2026, with 17.1 gigawatts of new wind, solar and storage capacity added to the grid in six months. Clean energy procurement also hit an all-time high of 14.5 gigawatts in signed purchase agreements, and the industry group said there is now enough clean power online in the United States to supply roughly 83 million homes. The growth came despite policy headwinds from Washington, underscoring continued momentum for renewables driven largely by falling costs and surging demand from data centers and electrification.
Read more →US clean energy deployment hits a record high, now enough to power 83 million homes
The American Clean Power Association reported on September 3, 2026, that US clean energy deployment reached a record high in the first half of 2026, with 17.1 gigawatts of new wind, solar and storage capacity added to the grid in six months. Clean energy procurement also hit an all-time high of 14.5 gigawatts in signed purchase agreements, and the industry group said there is now enough clean power online in the United States to supply roughly 83 million homes. The growth came despite policy headwinds from Washington, underscoring continued momentum for renewables driven largely by falling costs and surging demand from data centers and electrification.
Malaria research yields rare antibodies that could treat alpha-gal syndrome, the tick-bite meat allergy
NIH researchers announced on September 1, 2026, that they have identified rare antibodies with the potential to combat alpha-gal syndrome, a tick-bite-associated allergic condition that currently has no approved treatment or cure. The antibodies were discovered by accident: scientists were originally searching for antibodies that would target alpha-gal on malaria parasites to help prevent infection, and after isolating 42 candidates from malaria-exposed individuals, found 13 that instead bound tightly to the allergens responsible for alpha-gal syndrome. In laboratory tests published in the Journal of Clinical Investigation, the antibodies acted as a biological shield, successfully blocking human allergic antibodies from binding to red-meat allergens, opening a path toward the condition's first targeted treatment.
Read more →Malaria research yields rare antibodies that could treat alpha-gal syndrome, the tick-bite meat allergy
NIH researchers announced on September 1, 2026, that they have identified rare antibodies with the potential to combat alpha-gal syndrome, a tick-bite-associated allergic condition that currently has no approved treatment or cure. The antibodies were discovered by accident: scientists were originally searching for antibodies that would target alpha-gal on malaria parasites to help prevent infection, and after isolating 42 candidates from malaria-exposed individuals, found 13 that instead bound tightly to the allergens responsible for alpha-gal syndrome. In laboratory tests published in the Journal of Clinical Investigation, the antibodies acted as a biological shield, successfully blocking human allergic antibodies from binding to red-meat allergens, opening a path toward the condition's first targeted treatment.
Novartis pill shows strong results against multiple sclerosis relapses in late-stage trials
Novartis announced positive topline results on September 1, 2026, from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. Both studies met their primary endpoint, significantly reducing the annualized relapse rate compared with the standard drug teriflunomide (Aubagio), and remibrutinib beat the comparator on all key secondary endpoints, including reduction of MRI-visible brain lesions. The drug also showed a clinically meaningful delay in disability progression and a favorable safety profile with no liver safety signal. Novartis plans to present the full data at an upcoming medical conference in Toronto and submit the drug for approval to health authorities worldwide.
Read more →Novartis pill shows strong results against multiple sclerosis relapses in late-stage trials
Novartis announced positive topline results on September 1, 2026, from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. Both studies met their primary endpoint, significantly reducing the annualized relapse rate compared with the standard drug teriflunomide (Aubagio), and remibrutinib beat the comparator on all key secondary endpoints, including reduction of MRI-visible brain lesions. The drug also showed a clinically meaningful delay in disability progression and a favorable safety profile with no liver safety signal. Novartis plans to present the full data at an upcoming medical conference in Toronto and submit the drug for approval to health authorities worldwide.
Scientists discover vesper bats carry a never-before-seen dual immune system
Researchers from Tulane University, Stanford University and the CDC reported in early September 2026 that more than 500 species of vesper bats, the largest bat family on Earth, possess two entirely separate sets of antibody genes — an arrangement never before documented in any mammal. In the big brown bat, one gene set carries 33 antibody genes that mutate heavily to bind tightly to a single viral target, while the second holds 99 genes that stay less mutated so they can loosely recognize a much wider range of threats. The dual system may help explain the long-standing mystery of how bats carry and tolerate so many viruses, including ones deadly to humans, without becoming seriously ill themselves, and could point toward new strategies for antiviral research.
Read more →Scientists discover vesper bats carry a never-before-seen dual immune system
Researchers from Tulane University, Stanford University and the CDC reported in early September 2026 that more than 500 species of vesper bats, the largest bat family on Earth, possess two entirely separate sets of antibody genes — an arrangement never before documented in any mammal. In the big brown bat, one gene set carries 33 antibody genes that mutate heavily to bind tightly to a single viral target, while the second holds 99 genes that stay less mutated so they can loosely recognize a much wider range of threats. The dual system may help explain the long-standing mystery of how bats carry and tolerate so many viruses, including ones deadly to humans, without becoming seriously ill themselves, and could point toward new strategies for antiviral research.